Friday 6 November 2026 Export AXSM’s income statement to Excel — free account

Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $638.5 million, up 65.5% from fiscal 2024.

Revenue: +51.9%
EPS: +73.9%
Free cash flow: −1,078.3%
Total debt: +4.04%

Quarter to September 2026, against a year earlier

Revenue growth 3 yrs

132.13 2.33 +1.80%

Follow AXSM

Alert me

Market cap: $6.8B
P/E: 0.0×
Fwd P/E: −49.2×
Dividend yield: —
F-score: 5/9
Altman Z: 6.91
Beneish M: −2.53
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Axsome Therapeutics, Inc. 10-Q filed Aug 10, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed Aug 10, 2026 · accepted 4:07 PM ET · Document on sec.gov · Filing index

Red flags

Inventory outpacing revenue Aug 10, 2026
Inventory grew 105.4% while revenue grew 45.5% year over year

10-Q filed Aug 10, 2026 · The filing · sec.gov

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 4, 2026: 3 added · 2 removed · 24 modified; 7 with only figures updated

Modified · Commercial Products

Our commercial products ~~represent~~are our primary sources of revenue and are expected to be key contributors to future revenue growth.

Axsome Therapeutics, Inc. 10-Q filed Aug 10, 2026

Red flags

What changed

Stockrow Weekly